This view is supported by a study of 232 women born before 1915 who began taking daily estrogen tablets between 1969 and 1973 and continued for an average of 17.1 years. The difference was attributable mainly to less cardiovascular disease. In 1991, the FDA Advisory Committee on Maternal Health recommended that estrogen-replacement therapy be made available to virtually all postmenopausal women. For others, the question is whether an uncertain small risk for cancer is an acceptable tradeoff for HRT's well-documented benefits. References The Writing Group for the PEPI Trial.
Good answers spawn pressing questions.
Postmenopausal hormone use and risk of large-bowel cancer. Sturgeon SR and others. Evidence of a healthy estrogen user survivor effect. NIH Publication No. More important than ever.